TXN Price Hikes Suggest Demand Strength, but Premium Valuation Leaves Little Room for Error

What happened

Texas Instruments has reportedly begun raising prices as chip demand strengthens, according to Zacks, adding a potential lever for revenue and margin expansion beyond unit volume growth. The move aligns with the Q1’26 recovery signals highlighted in TI’s filings, where industrial and data-center shipments drove a 19% YoY revenue increase and operating margin reached 37.5%. However, the stock already trades at 45.6x trailing earnings and 31x EV/EBITDA, implying the market has priced in a sustained multi-quarter recovery with little margin for disappointment. Any price increases must be sustained without triggering customer pushback or demand destruction, especially given TI’s heavy exposure to China (about 50% of revenue shipped there) and ongoing tariff uncertainties. Thus, while the news is incrementally positive, it does not eliminate the key risks of a false-start recovery or inventory rebuild that could reverse the recent momentum.

Implication

For investors, the reported price increases suggest TI is seeing enough demand strength to exercise pricing power, which could help offset rising costs and support margins if sustained. However, the stock’s rich valuation already embeds a strong recovery, so the real question is whether price hikes translate into higher ASPs without sacrificing volume or market share. Given that TI’s own management has acknowledged a prior ‘head fake’ in demand and that inventory days remain elevated at 209, the risk of a short-lived pricing cycle is elevated. Tariff and trade risks, particularly around China, could also undermine the benefits if customers accelerate orders now only to pause later. Consequently, investors should wait for Q2’26 revenue to land within the $5.0–5.4B guidance and inventory days to fall below 200 before adding exposure; attractive entry remains near $230, while trimming above $290 is warranted.

Thesis delta

The price increase news is a modest positive that aligns with the existing recovery thesis but does not change the WAIT rating. It adds to the evidence that demand is firming, but the market already prices this in, and the critical test remains Q2’26 execution. The thesis delta is neutral-to-slightly-positive, with no change to the trim/entry levels.